Trials / Terminated
TerminatedNCT05067972
A Study of PF-07260437 in Advanced or Metastatic Solid Tumors
A PHASE 1 DOSE ESCALATION AND EXPANSION STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETIC, PHARMACODYNAMIC, AND ANTITUMOR ACTIVITY OF PF-07260437 IN ADVANCED OR METASTATIC SOLID TUMORS
- Status
- Terminated
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 30 (actual)
- Sponsor
- Pfizer · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
A study to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and antitumor activity of PF-07260437, a B7-H4 x CD3 bispecific mAb, in participants aged ≥18 years of age with advanced or metastatic breast cancer, ovarian cancer or endometrial cancer. Adult participants with other advanced or metastatic high B7-H4 expressing tumors may be considered after discussion with and approval from sponsor.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | PF-07260437 | B7-H4 x CD3 bi-specific mAb |
| DIAGNOSTIC_TEST | B7-H4 IHC | B7-H4 expression |
Timeline
- Start date
- 2021-10-07
- Primary completion
- 2023-10-17
- Completion
- 2023-10-17
- First posted
- 2021-10-05
- Last updated
- 2025-05-06
- Results posted
- 2025-05-06
Locations
15 sites across 2 countries: United States, Puerto Rico
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT05067972. Inclusion in this directory is not an endorsement.